Physician profile
Aaron S Katz
NPI 1487654380
$10,249.78
in general payments reported to CMS, 2019-2025
34 companies · $1,776 in 2025
The $1,776 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $1,073 · 2021: $1,337 · 2022: $1,629 · 2023: $1,478 · 2024: $1,905 · 2025: $1,776.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950 · Education: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,949.68 |
| Education | $208.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,695.88 | 2019-2025 | |
| Janssen Biotech, INC. | $1,499.50 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $1,241.53 | 2019-2025 | |
| Genzyme Corporation | $674.55 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $572.15 | 2019-2025 | Ilumya, Winlevi |
| Lilly USA, LLC | $561.95 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $545.10 | 2019-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $477.32 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $436.01 | 2020-2025 | |
| Ucb, INC. | $424.21 | 2019-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $349.40 | 2019-2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $277.49 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $217.02 | 2022-2025 | Sotyktu |
| Incyte Corporation | $211.22 | 2022-2025 | Opzelura |
| Dermavant Sciences, INC. | $140.17 | 2023-2024 | Vtama |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.51 | 2020-2025 | Jublia, Cabtreo, Siliq |
| Galderma Laboratories, L.P. | $100.66 | 2020-2025 | Nemluvio |
| Genentech USA, INC. | $85.93 | 2019-2023 | Erivedge |
| Almirall LLC | $85.85 | 2019-2025 | Klisyri |
| Dermira, INC. | $75.73 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $72.48 | 2019-2020 | |
| Celgene Corporation | $71.08 | 2019 | |
| Vyne Pharmaceuticals INC. | $70.73 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.47 | 2022-2025 | Spevigo |
| Merck Sharp & Dohme LLC | $31.16 | 2024 | Keytruda |
| Botanix Sb INC | $22.22 | 2025 | Sofdra |
| Fresenius Kabi USA, LLC | $21.80 | 2023 | Idacio |
| Epi Health, LLC | $17.59 | 2022 | |
| Nabriva Therapeutics, Plc | $16.94 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.24 | 2025 | Ycanth |
| Organon LLC | $15.48 | 2025 | Vtama |
| Allergan, INC. | $15.14 | 2019 | |
| Mylan Pharmaceuticals INC. | $14.10 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.